Safety, Tolerability, and Efficacy Of Hizentra® In Japanese Patients With Primary Immunodeficiency Over 48 Weeks
Kohsuke Imai(National Defense Medical College Hospital), Toshio Miyawaki(University of Toyama), Tadashi Ariga(Tokai University), Shigeaki Nonoyama(National Defense Medical College), Martin Bexon(Bexon Clinical Consulting (United States)), Mikhail Rojavin(CSL (United States)), Midori Kobayashi(FIND), Masafumi Yamada(Hokkaido University Hospital), Toshiro Hara(Fukuoka Children's Hospital and Medical Center for Infectious Diseases), Hidetoshi Takada, Hirokazu Kanegane(Tokyo Medical and Dental University)
Cited by 1
Related Papers
The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-IgM syndrome
|Cell|1993|824
Common Defects of ABCG2, a High-Capacity Urate Exporter, Cause Gout: A Function-Based Genetic Analysis in a Japanese Population
|Science Translational Medicine|2009|438
Mutations in Glucose Transporter 9 Gene SLC2A9 Cause Renal Hypouricemia
|The American Journal of Human Genetics|2008|386
Smad2 and Smad3 Are Redundantly Essential for the TGF-β–Mediated Regulation of Regulatory T Plasticity and Th1 Development
|The Journal of Immunology|2010|325